Prokarium’s Vaxonella platform is based on attenuated Salmonella Typhi strain ZH9, a typhoid vaccine that has completed Phase I and II clinical trials and been safely dosed to 471 volunteers (including 101 children). Although typhoid remains the primary cause of enteric fever, with 22 million cases and 200,000 deaths per year, its close relative Salmonella Paratyphi is a pathogen of growing importance, causing 6 million cases of enteric fever per year. Prokarium has plans to develop a dual typhoid-paratyphoid vaccine to combat enteric fever and is actively looking for a development partner.